Nanostics AI ClarityDX Prostate Study Improves Cancer Detection
EDMONTON, Alberta, April 20, 2026 Nanostics Inc. has announced the publication of a peer-reviewed study validating its AI-powered ClarityDX®...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
EDMONTON, Alberta, April 20, 2026 Nanostics Inc. has announced the publication of a peer-reviewed study validating its AI-powered ClarityDX®...
Ingelheim, Germany, April 20, 2026 Boehringer Ingelheim has announced a major strategic expansion of its computational innovation capabilities with...
MILWAUKEE, Feb. 14, 2026 — New research presented at the AAAAI Annual Meeting 2026 demonstrates that machine learning (ML)...
Stanford, California, January 21, 2026 — Researchers at Stanford University announced in January 2026 the development of a machine-learning...
CAMBRIDGE, Mass. | January 8, 2026 — Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibody therapies, announced the...
SAN DIEGO | January 8, 2026 — Just – Evotec Biologics, a collaboration between Evotec SE and Just –...
Boston, December 18, 2025 — A revolutionary single-track data transformation approach is emerging as a powerful solution to one...
Dallas, Texas, October 30, 2025 — Lantern Pharma Inc. (NASDAQ: LTRN) announced it will present two cutting-edge AI-driven drug-development...
